IMVT
Immunovant, Inc. NASDAQ Listed Jun 21, 2019$27.23
Mkt Cap $5.5B
52w Low $13.36
82.9% of range
52w High $30.09
50d MA $26.20
200d MA $22.37
P/E (TTM)
-9.9x
EV/EBITDA
-4.3x
P/B
5.8x
Debt/Equity
0.0x
ROE
-41.9%
P/FCF
-6.9x
RSI (14)
—
ATR (14)
—
Beta
0.67
50d MA
$26.20
200d MA
$22.37
Avg Volume
1.4M
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
320 West 37th Street · New York City, NY 10018 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 6, 2026 | AMC | -0.72 | -0.61 | +15.3% | 27.05 | +2.4% | +1.6% | -1.4% | -4.1% | -5.2% | -4.8% | — |
| Nov 10, 2025 | AMC | -0.72 | -0.73 | -1.4% | 23.37 | +0.0% | -2.1% | +0.3% | -2.4% | +1.6% | +4.0% | — |
| Aug 11, 2025 | AMC | -0.69 | -0.60 | +13.0% | 14.76 | +0.6% | +3.0% | +7.7% | +3.0% | +3.1% | +3.4% | — |
| May 29, 2025 | AMC | -0.71 | -0.64 | +10.3% | 14.89 | -0.8% | -0.3% | +3.5% | +3.7% | +3.0% | +7.6% | — |
| Feb 6, 2025 | AMC | -0.73 | -0.76 | -4.1% | 20.36 | +0.0% | +0.2% | -4.1% | -5.0% | -5.6% | -2.5% | — |
| Nov 7, 2024 | AMC | -0.60 | -0.74 | -23.3% | 29.93 | -0.1% | +2.4% | +4.0% | -2.2% | -3.4% | -6.3% | — |
| Aug 6, 2024 | AMC | -0.53 | -0.60 | -13.2% | 27.85 | +0.3% | -3.1% | +1.0% | +4.9% | +6.4% | +7.0% | — |
| May 29, 2024 | AMC | -0.43 | -0.52 | -20.9% | 29.57 | -6.3% | -10.7% | -14.1% | -14.8% | -14.7% | -13.4% | — |
| Feb 12, 2024 | AMC | -0.43 | -0.36 | +16.3% | 36.69 | -2.3% | +0.6% | +3.0% | +3.0% | +1.2% | +2.2% | — |
| Nov 9, 2023 | AMC | -0.47 | -0.45 | +4.3% | 31.31 | +1.7% | +4.2% | +4.8% | +11.7% | +9.4% | +7.7% | — |
| Aug 10, 2023 | AMC | -0.45 | -0.57 | -26.7% | 22.32 | +0.5% | +0.7% | -4.8% | -8.1% | -7.5% | -12.2% | — |
| May 22, 2023 | AMC | -0.43 | -0.46 | -7.0% | 23.75 | +0.6% | -6.4% | -10.7% | -11.3% | -11.4% | -12.3% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $26.55 | $26.89 | +1.3% | +3.3% | +3.0% | +10.4% | +7.5% | +6.5% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.49 | $27.50 | +0.0% | -2.9% | -5.6% | -6.7% | -6.3% | -4.4% |
| Feb 9 | Guggenheim | Maintains | Buy → Buy | — | $27.05 | $27.69 | +2.4% | +1.6% | -1.4% | -4.1% | -5.2% | -4.8% |
| Jan 8 | Truist | Maintains | Hold → Hold | — | $26.73 | $26.32 | -1.5% | -1.6% | -2.6% | -3.4% | -2.1% | +2.3% |
| Jan 6 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $24.97 | $25.83 | +3.4% | +3.7% | +7.0% | +5.4% | +4.2% | +3.4% |
| Dec 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $26.42 | $26.73 | +1.2% | -1.6% | +0.7% | +2.1% | -0.9% | +1.0% |
| Sep 30 | JP Morgan | Maintains | Overweight → Overweight | — | $16.06 | $15.88 | -1.1% | +0.4% | +1.7% | +4.2% | +5.2% | +3.1% |
| Sep 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.70 | $16.58 | -0.7% | -3.5% | +2.6% | -2.0% | -1.8% | -3.0% |
| Aug 12 | BofA Securities | Maintains | Buy → Buy | — | $14.76 | $14.85 | +0.6% | +3.0% | +7.7% | +3.0% | +3.1% | +3.4% |
| Aug 12 | JP Morgan | Maintains | Overweight → Overweight | — | $14.76 | $14.85 | +0.6% | +3.0% | +7.7% | +3.0% | +3.1% | +3.4% |
| Jul 28 | UBS | Maintains | Neutral → Neutral | — | $16.95 | $17.14 | +1.1% | -1.1% | -1.8% | -1.9% | -5.1% | -7.3% |
| Apr 22 | UBS | Downgrade | Buy → Neutral | — | $14.46 | $14.41 | -0.3% | -1.5% | -0.1% | +4.2% | +1.8% | +6.6% |
| Mar 20 | BofA Securities | Maintains | Buy → Buy | — | $18.88 | $18.64 | -1.3% | +4.3% | +4.0% | +3.0% | -3.7% | -5.2% |
| Mar 20 | Guggenheim | Maintains | Buy → Buy | — | $18.88 | $18.64 | -1.3% | +4.3% | +4.0% | +3.0% | -3.7% | -5.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.79 | $17.41 | -7.3% | +0.5% | +4.8% | +4.5% | +3.5% | -3.2% |
| Mar 10 | Guggenheim | Maintains | Buy → Buy | — | $20.02 | $19.89 | -0.6% | +1.4% | -2.0% | -4.5% | -6.1% | -2.5% |
| Feb 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.41 | $20.65 | +1.2% | -4.4% | -5.2% | -5.8% | -2.7% | -0.4% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $20.41 | $20.65 | +1.2% | -4.4% | -5.2% | -5.8% | -2.7% | -0.4% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.36 | $20.36 | +0.0% | +0.2% | -4.1% | -5.0% | -5.6% | -2.5% |
| Jan 15 | BofA Securities | Maintains | Buy → Buy | — | $22.88 | $23.35 | +2.1% | +6.6% | +4.0% | +4.3% | +3.1% | +1.5% |
| Jan 3 | Wolfe Research | Downgrade | Outperform → Peer Perform | — | $25.19 | $24.52 | -2.7% | -1.5% | -2.2% | -2.2% | -6.2% | -6.8% |
| Dec 19 | Wells Fargo | Maintains | Overweight → Overweight | — | $26.25 | $26.33 | +0.3% | -2.2% | -1.5% | -1.9% | -0.6% | -2.0% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.93 | $29.91 | -0.1% | +2.4% | +4.0% | -2.2% | -3.4% | -6.3% |
| Oct 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $29.61 | $29.74 | +0.4% | +1.4% | +1.1% | +2.7% | -0.6% | -3.6% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $28.02 | $27.65 | -1.3% | +1.7% | +1.5% | +5.4% | +4.5% | +8.9% |
| Sep 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.44 | $31.65 | +0.7% | -5.5% | -7.6% | -8.2% | -5.6% | -6.4% |
| Aug 13 | UBS | Maintains | Buy → Buy | — | $29.64 | $29.99 | +1.2% | +0.5% | +1.8% | +4.2% | +1.4% | +5.2% |
| Aug 8 | JP Morgan | Maintains | Overweight → Overweight | — | $26.98 | $27.29 | +1.1% | +4.2% | +8.3% | +9.9% | +10.4% | +11.8% |
| Jun 3 | Oppenheimer | Maintains | Outperform → Outperform | — | $25.39 | $25.21 | -0.7% | -0.7% | -0.6% | +0.8% | +0.2% | -0.9% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $29.57 | $27.70 | -6.3% | -10.7% | -14.1% | -14.8% | -14.7% | -13.4% |
| May 30 | HC Wainwright& Co. | Maintains | Buy → Buy | — | $29.57 | $27.70 | -6.3% | -10.7% | -14.1% | -14.8% | -14.7% | -13.4% |
| Mar 25 | Truist | Maintains | Buy → Buy | — | $32.20 | $32.42 | +0.7% | -3.0% | -2.4% | +1.0% | +0.3% | -1.8% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.18 | $40.41 | +11.7% | +8.1% | +14.6% | +22.1% | +20.4% | +17.1% |
| Dec 21 | BofA Securities | Maintains | Buy → Buy | — | $36.18 | $40.41 | +11.7% | +8.1% | +14.6% | +22.1% | +20.4% | +17.1% |
| Dec 1 | UBS | Maintains | Buy → Buy | — | $39.13 | $39.35 | +0.6% | +3.6% | +4.3% | +2.0% | -0.3% | +2.9% |
| Nov 15 | Truist | Maintains | Buy → Buy | — | $34.97 | $34.97 | +0.0% | -2.1% | -3.6% | -3.3% | -3.3% | -5.7% |
| Oct 24 | Piper Sandler | Maintains | Overweight → Overweight | — | $33.80 | $34.64 | +2.5% | +3.6% | +0.5% | +1.3% | -1.1% | -2.6% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $33.80 | $34.64 | +2.5% | +3.6% | +0.5% | +1.3% | -1.1% | -2.6% |
| Oct 16 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $37.41 | $37.53 | +0.3% | +0.9% | +0.0% | -1.2% | -4.1% | -6.3% |
| Oct 13 | UBS | Upgrade | Neutral → Buy | — | $35.28 | $36.78 | +4.3% | +6.0% | +7.0% | +6.1% | +4.7% | +1.7% |
| Oct 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $36.23 | $35.72 | -1.4% | +2.8% | +2.6% | +1.1% | -2.6% | +3.3% |
| Sep 27 | Raymond James | Upgrade | Market Perform → Outperform | — | $39.96 | $42.50 | +6.4% | -1.1% | -0.4% | -3.9% | -13.3% | -14.2% |
| Sep 27 | Wells Fargo | Maintains | Overweight → Overweight | — | $39.96 | $42.50 | +6.4% | -1.1% | -0.4% | -3.9% | -13.3% | -14.2% |
| Sep 27 | Citigroup | Maintains | Buy → Buy | — | $39.96 | $42.50 | +6.4% | -1.1% | -0.4% | -3.9% | -13.3% | -14.2% |
| Sep 26 | Truist | Maintains | Buy → Buy | — | $20.28 | $32.29 | +59.2% | +97.0% | +94.8% | +96.2% | +89.3% | +70.8% |
| Sep 22 | Guggenheim | Maintains | Buy → Buy | — | $21.25 | $21.27 | +0.1% | -4.0% | -4.6% | +88.0% | +86.0% | +87.2% |
| Sep 18 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $21.81 | $21.98 | +0.8% | +0.6% | -1.5% | -5.5% | -2.6% | -6.5% |
| Aug 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $20.58 | $20.63 | +0.2% | -0.0% | -1.7% | -2.8% | -2.5% | +2.2% |
| Aug 16 | Truist | Maintains | Buy → Buy | — | $20.52 | $20.62 | +0.5% | +0.6% | -4.5% | -0.2% | +0.3% | +0.2% |
| Aug 11 | Citigroup | Maintains | Buy → Buy | — | $22.32 | $22.44 | +0.5% | +0.7% | -4.8% | -8.1% | -7.5% | -12.2% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 1, 2026 | Susman Robert GrahamDir | — | Sell | 2,502 | $27.17 | $68K | 36,394 | +2.69% | — |
Data updated apr 25, 2026 3:25pm
· Source: massive.com